RE: I17 Jul 2020 18:11
I appreciate that you got the resistance levels off of "marketscreener" but a quick check on there technicals for other stocks that have performed well shows that they are not to be believed. I also agree that many of the RNS released over the past year or so have been negative or neutral but I also think it is down to interpretation which in turn has lead to overreaction. There have been positives that seem to have been overlooked. Broker ratings don't help even if most know that the brokers do the opposite of the rating.
Aside from the 922m goodwill impairment charge the interim results were pretty reasonable; some positives being:
Impact of COVID-19 largely mitigated at Adjusted EBITDA1 level due to close management of the cost base. Adjusted EBITDA margin1 (after adopting IFRS 16) of 38.0% (30 April 2019: 39.9% CCY). Only 2% difference.
The Group continues to make progress against our strategic initiatives to improve operational efficiency and simplification, as well as to strengthen our product alignment with customer needs. Accordingly, we continue to make incremental investments in our operations as far as possible in light of COVID-19.
· Successful refinancing of $1.4bn Term Loan in May 2020. The Group has no term loan maturities until June 2024.
·
The Group had cash and cash equivalents of $808.1m as at 30 April 2020 (31 October 2019: $355.7m), which reflects $633.1m of Operating cash1 and $175.0m of RCF drawn as a precautionary measure. The Group's available liquidity totals $1.1bn.
·
Strong cash performance, with Adjusted Cash Conversion1 of 131.5% (30 April 2019: 115.1%) and free cash flow1 of $304.9m in the six months ended 30 April 2020 (30 April 2019: $419.5m).
·
Cash generated from operating activities of $560.4m for the six months ended 30 April 2020 (30 April 2019: $622.6m).
Increase Major holdings since June 2020:
BlackRock, Inc. increase from 4.27% to 5.53%
M&G Plc 5.02%
Causeway Capital Management LLC 4.88%